About Our Company

Our History

  Only ongoing agreements and public funds are listed
Feb.2000  Founded Renascience Inc. as an academic bio-venture company in Kanagawa, Japan
Oct.2016  License agreement with Eirion Therapeutics, Inc., USA for dermatological indications
Dec.2019  Adopted as an AMED’s Cyclic Innovation for Clinical Empowerment (CiCLE) program(Project for premenstrual syndrome/premenstrual dysphoric mood disorder)
Dec.2019  Concluded an option agreement with ASKA Pharmaceutical Co., Ltd. for a license agreement of pyridoxamine on premenstrual syndrome / premenstrual dysphoric mood disorder
May.2020  License agreement with Global Medical Device Company for Ultrafine Endoscopes
Jul.2020  Signed an agreement with CHEST M.I., Inc. for the joint development and commercialization of respiratory AI solutions
Dec.2020  Initiated a PhaseⅡ investigator-initiated clinical study on premenstrual syndrome/premenstrual dysphoric mood disorder
Dec.2020  Option agreement with Daiichi Sankyo Co., Ltd. for the treatment of respiratory diseases including COVID-19 pneumonia and other lung injuries
May.2021  Collaboration agreement with Nipro Corporation for the development of chronic dialysis support system using artificial intelligence (AI)
May.2021  Selected as AMED Translational Research Program, seeds C (Malignant melanoma project)
Jul.2021  Initiated a PhaseⅡ investigator-initiated clinical study on malignant melanoma
Sep.2021  Listed on the Tokyo Stock Exchange Mothers market (current Growth market, securities code: 4889)
Jan.2022  Open Tohoku University Renascience Open Innovation Labo (TREx)
Mar.2022  Adopted as a sharing organization in an AMED’s Research program for Practical Application of Innovative Cancer Medicine (CML project)
Apr.2022  Adopted as an AMED’s Commercialization Promotion Project for Medical-engineering Collaboration (Support for small and medium-sized enterprises development and commercialization)
Jun.2022  Transitions from a Company with Corporate Auditors to a Company with an Audit Committee, and Introduction of Executive Officer System
Aug.2022  Initiation of dosing in a PhaseⅢ study of chronic myeloid leukemia
Sep.2022  Collaboration Agreement with HI-LEX Corporation and its Subsidiary HI-LEX Medical
Nov.2022  Memorandum of Understanding with NEC Solution Innovators, Ltd.
Dec.2022  Regulatory Approval of Ultrafine Disposable Endoscope
Feb.2023  Adoption of AMED Research on Development of New Medical Devices (AI Project Supporting Chronic Dialysis System)
Mar.2023  Adoption in AMED Practical Research Program for Intractable Diseases (Systemic Scleroderma Project)
Apr.2023  Results of Placebo-Controlled, Double-Blind, PhaseⅡ Investigator-Initiated Clinical Trial of RS5614, a PAI-1 Inhibitor, for Novel Coronavirus (SARS-CoV-2) Pneumonia
Apr.2023  Open Hiroshima University Renascience Open Innovation Labo (HiREx)
Jun.2023  Collaboration Agreement with Kyoto University and Daiichi Sankyo Company, Limited
Jun.2023  Comprehensive Collaboration Agreement with NEC Corporation on AI projects
Jun.2023  Results of PhaseⅡ Investigator-Initiated Clinical Trial to Evaluate the Safety and Efficacy of RS5614 in Combination with Nivolumab for the Treatment of Malignant Melanoma
Aug.2023  PAI-1 Inhibitor RS5614 Met Primary Endpoint in Phase II Investigator-Initiated Clinical Trial for Unresectable Malignant Melanoma Refractory to Nivolmab
Aug.2023  Achievement of Enrollment Goal in Phase II Investigator-Initiated Clinical Trial of RS8001 (pyridoxamine) for the Treatment of Patients with Psychiatric Symptoms of Premenstrual Syndrome/Premenstrual Dysphoric Disorder
Sep.2023  Initiation of Phase II Study for Non-Small Cell Lung Cancer
Oct.2023  Initiation of Phase II study for interstitial lung disease associated with systemic scleroderma
Oct.2023  Initiation of Phase II Study for Cutaneous Angiosarcoma
Dec.2023  Conclusion of Collaboration Agreement with Toray Medical Co., Ltd